Mark D. Erion

机构：Merck & Co., Inc., Rahway, NJ, USA (United States), Johnson & Johnson (United States), Springhouse, Janssen (United States)

发表论文 181 篇 · 总被引 8254 次 · h-index 52

代表论文

• Targeting a ceramide double bond improves insulin resistance and hepatic steatosis (2019 · Science · 被引 464)
• Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy (2017 · Science · 被引 355)
• Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist # (2008 · Hepatology · 被引 210)
• Discovery of a Series of Phosphonic Acid-Containing Thiazoles and Orally Bioavailable Diamide Prodrugs That Lower Glucose in Diabetic Animals Through Inhibition of Fructose-1,6-Bisphosphatase (2010 · Journal of Medicinal Chemistry · 被引 161)
• Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents (2012 · Biopolymers · 被引 135)
• Engineering Glucose Responsiveness Into Insulin (2017 · Diabetes · 被引 95)